Table 2. Relationship between Slug expression and clinic-pathological parameters in breast cancer patients.
| Features | Slug expression (%) |
χ2 | P-value | |
|---|---|---|---|---|
| Low (n=232) | High (n=176) | |||
| Age | ||||
| ⩽50 | 68 (29.3) | 54 (30.7) | 0.090 | 0.76 |
| >50 | 164 (70.7) | 122 (69.3) | ||
| Tumor size | ||||
| T1 | 53 (22.8) | 39 (22.2) | 1.87 | 0.6 |
| T2 | 136 (58.6) | 112 (63.6) | ||
| T3 | 32 (13.8) | 17 (9.7) | ||
| T4 | 10 (4.3) | 8 (4.5) | ||
| N/A | 1 (0.4) | |||
| Nodal status | ||||
| N0 | 121 (52.2) | 79 (44.9) | 2.23 | 0.53 |
| N1 | 70 (30.2) | 61 (34.7) | ||
| N2 | 27 (11.6) | 25 (14.2) | ||
| N3 | 14 (6.0) | 11 (6.3) | ||
| AJCC stage | ||||
| I | 40 (17.2) | 27 (15.3) | 0.71 | 0.87 |
| II | 128 (55.2) | 102 (58.0) | ||
| III | 49 (21.1) | 39 (22.2) | ||
| IV | 9 (3.9) | 5 (2.8) | ||
| N/A | 6 (2.6) | 3 (1.7) | ||
| Metastasis status | ||||
| M0 | 222 (95.7) | 172 (97.7) | 0.85 | 0.36 |
| M1 | 9 (3.9) | 4 (2.3) | ||
| No data | 1 (0.4) | |||
| ER | ||||
| Negative | 30 (12.9) | 68 (38.6) | 34.24 | <0.000 |
| Positive | 195 (84.1) | 108 (61.4) | ||
| N/A | 7 (3.0) | |||
| PR | ||||
| Negative | 63 (27.2) | 91 (51.7) | 23.46 | <0.000 |
| Positive | 162 (69.8) | 85 (48.3) | ||
| N/A | 7 (3.0) | |||
| Her2 | ||||
| Negative | 191 (82.3) | 139 (79) | 0.84 | 0.36 |
| Positive | 32 (13.8) | 30 (17) | ||
| N/A | 9 (3.9) | 7 (4) | ||
| Molecular subtype | ||||
| Luminal A/B | 177 (76.3) | 88 (50) | 33.98 | <0.000 |
| Her2-enriched | 22 (9.5) | 26 (14.8) | ||
| Basal-like | 27 (11.6) | 57 (32.4) | ||
| Normal-like | 6 (2.6) | 5 (2.8) | ||
Abbreviations: ERα, estrogen receptor α N/A, not available; TCGA, The Cancer Genome Atlas.
Note: 408 breast cancer samples with z-scores of protein level were from the TCGA database. The expression of Slug and ERα measured by reverse-phase protein array was directly obtained from the online data (www.cbioportal.org). P-value was calculated using Pearson χ2-test.